Activating JAK2 point mutations are implicated in the pathogenesis of myeloid and lymphoid malignancies, including high-risk B-cell acute lymphoblastic leukemia (B-ALL). The gene discussed is JAK2; the disease is B-cell acute lymphoblastic leukemia.